The Dynamics of Cardio-Vascular Risk Stratification in Patients with Cancer

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.

Dr Maryam Lustberg is an Associate Professor with Tenure in the Division of Medical Oncology at The Ohio State University, where she specialize in treating patients with breast cancer at The Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James). In July 1, she joins Yale School of Medicine as an Associate Professor, Chief of Breast Medical Oncology and the Director of Yale Breast Center. Her research focuses on improving long-term outcomes for breast cancer patients who have developed side effects associated with treatment, and on investigating novel blood-based biomarkers to identify recurrence and treatment toxicity earlier. She joined the Division of Medical Oncology in August 2010 after completing internal medicine residency at the University of Maryland and a three-year combined medical oncology and breast medical oncology fellowship at Ohio State (2007-2010). She also obtained a Master’s of Public Health (MPH) in Clinical Investigation from Ohio State’s College of Public Health in 2010. She is physician champion and translational researcher in cancer supportive care services focusing on expanding research, clinical care and programs for individuals diagnosed with cancer and serves on the MASCC Board of Directors. She is serving as President Elect of MASCC from 2020 – 2022.

Sebastian Szmit graduated from the Military Medical Academy in Poland. He began cardio- oncology activities in 2006 by working for the Department of Oncology of the Military Institute of Medicine. Sebastian Szmit was appointed the executive editor of the Task Force of National Consultants in Cardiology and Clinical Oncology, to develop the first two Polish documents of for Recommendations on cardiologic safety of patients with breast cancer (published in 2010) and lung cancer (published in 2012). Since 2012 he has served as the cardio-oncology consultant at the Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, and since 2015 as the scientific director of the training in Oncology and in Cardiology; at the Centre of Postgraduate Medical Education in Poland. He is the cardio-oncology research coordinator for the Polish Lymphoma Research Group and the Polish National Oncology Network.  He co-authored two educational books: Hypertension-oncology: arterial hypertension in cancer disease; and Cardiovascular complications in cancer patients; published in 2018 under auspices of the Polish Society of Clinical Oncology, Since 2019 he has been a Member of the Executive Committee of the Global Cardio- Oncology Summit (GCOS) and a Member of the Education & Training Advisory Committee of the International Cardio-Oncology Society (IC-OS). Since 2020 he has been an Honorary Member of the Cardio-Oncology Society of Southern Africa (COSOSA), a Fellow of the International Cardio-Oncology Society (FICOS), and a Board Member of the European Society of Cardiology (ESC) Council of Cardio-Oncology. On his initiative, on May 26th 2021, the Scientific Council of the Centre of Postgraduate Medical Education decided to create the Cardiooncology Department with Echocardiography Laboratory; based at two hospitals: (1) European Health Centre in Otwock (oncology center); (2) Institute of Hematology and Transfusion Medicine in Warsaw.

Dr. Sonis is senior academic at Harvard, Brigham and Women’s Hospital and the Dana-Farber Cancer Institute and a world-renowned expert on tissue injury associated with cancer therapy.  His development of predictive models has enabled the investigation of the biological basis of cancer regimen-related tissue toxicities and has stimulated the development of potential therapies.  Dr. Sonis’ interest in the pathobiology associated with toxicity risk has led to innovative omics-based analytical approaches to clinically actionable outcomes to personalize therapy.  He is the former President of Triad, an international not-for-profit company which focused on the adverse health and economic outcomes of cancer treatment toxicities and has served as a special employee of the FDA.  Dr. Sonis is the founder of several companies focused on various aspects of translational and precision medicine.  His first company, Biomodels, a pre-clinical research organization, was spun out of Brigham and Women’s Hospital in 1997 and has catalyzed the development of drugs, devices, and biologicals for a variety of indications for companies ranging from start-ups to big pharma.  A spin-off, Primary Endpoint Solutions (PES) assists companies throughout the clinical development process including the identification and validation of endpoint-related biomarkers and omics to define predictive patient response.  Dr. Sonis has published extensively on the clinical, biological, and health economic aspects of cancer and complications associated with its treatment.  He holds several patents and is the author of more than 300 original publications, reviews, and chapters and 11 books.  He received his DMD from Tufts, completed his DMSc and residency at Harvard, and his postdoctoral training in tumor immunology at Oxford University (UK) where he was a Knox Fellow.